Rosenblatt Securities set a bold $1,300 price target on LITE with a fresh Buy rating. The photonics and laser company carries an $85 billion market cap. Short interest sits at 8.5% of free float — modest enough not to complicate any rally.
Oppenheimer also made a bullish call, initiating VTRS at Buy with a $25 target. Viatris, the generic drug giant with a nearly $20 billion market cap, has attracted little short seller attention at just 3.3% SI of free float. The initiation signals renewed confidence in the company's turnaround strategy.
On the downgrade side, CHRW saw its consensus target trimmed to $197.56 from $199.40. The freight brokerage firm has faced pressure as shipping markets remain choppy.
Elsewhere, GRMN picked up a target price lift to $302 from $290. AMZN consensus crept up to $329.29, reflecting steady bullish sentiment with 57 analysts holding Buy ratings.
REGN also saw its average target nudge higher to $850.88. The biotech has 17 Buy ratings and remains a consensus favourite despite ongoing pricing pressures in the pharmaceutical sector.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
